The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 788-794 , October 2008

A differential effect of 2 probiotics in the prevention of eczema and atopy: A double-blind, randomized, placebo-controlled trial

  • Kristin Wickens, PhD

      Affiliations

    • Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • Corresponding Author InformationReprint requests: Kristin Wickens, PhD, Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, P O Box 7343, Wellington South, Wellington, New Zealand.
    • ,
  • Peter N. Black, FRACP

      Affiliations

    • Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    • ,
  • Thorsten V. Stanley, FRCP

      Affiliations

    • Department of Paediatrics, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • ,
  • Edwin Mitchell, FRACP, DSc

      Affiliations

    • Department of Paediatrics, University of Auckland, Auckland, New Zealand
    • ,
  • Penny Fitzharris, FRACP

      Affiliations

    • Immunology Department, Auckland Hospital, Auckland, New Zealand
    • ,
  • Gerald W. Tannock, PhD

      Affiliations

    • Department of Microbiology and Immunology, University of Otago, Wellington, New Zealand
    • ,
  • Gordon Purdie, BSc

      Affiliations

    • Department of Public Health, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • ,
  • Julian Crane, FRACP

      Affiliations

    • Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    • ,
  • Probiotic Study Group

Received 9 April 2008 ,Revised 3 July 2008 ,Accepted 14 July 2008.

References 

  1. Strachan D. Family size, infection and atopy: the first decade of the “hygiene hypothesis”. Thorax. 2000;55(suppl 1):S2–S10
  2. Sepp E, Julge K, Vasar M, Naaber P, Bjorksten B, Mikelsaar M. Intestinal microflora of Estonian and Swedish infants. Acta Paediatr. 1997;86:956–961
  3. Vaarala G. Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy. 2003;33:1634–1640
  4. Blumer N, Sel S, Virna S, Patrascan C, Zimmermann S, Herz U, et al. Perinatal maternal application of Lactobacillus rhamnosus GG suppresses allergic airway inflammation in mouse offspring. Clin Exp Allergy. 2007;37:348–357
  5. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357:1076–1079
  6. Kalliomaki M, Salminen S, Poussa T, Arvillommi H, Isolauri E. Probiotics and prevention of atopic disease: 4 year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361:1869–1871
  7. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:1019–1021
  8. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Probiotics and prebiotics galacto-oligosaccharides in the prevention of allergic disease: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:192–198
  9. Abrahamsson T, Jakobsson T, Bottcher M, Fredrikson M, Jenmalm M, Oldaeus NBG. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:1174–1180
  10. Taylor A, Dunstan J, Prescott S. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol. 2007;119:184–191
  11. Kopp M, Hennemuth I, Heinzmann A, Urrbanek R. Randomized, double-blind, placebo-controlled trial for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics. 2008;121:e1–e7
  12. Williams HC, Burney PGJ, Hay RJ, Archer CB, Shipley MJ, Hunter JJA, et al. The UK Working Party's Diagnostic Criteria for Atopic Dermatitis. Br J Dermatol. 1994;131:383–396
  13. Williams H. So how do I define atopic eczema? a practical manual for researchers wishing to define atopic eczema. 1996. Available at: http://www.nottingham.ac.uk/dermatology/eczema/contents/html Accessed August 8, 2008.
  14. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186:23–31
  15. ASCIA Skin Prick Testing Working Party. Skin prick testing for the diagnosis of allergic disease: a manual for practitioners. 2006. Available at: http://www.allergy.org.au/images/stories/pospapers/ASCIA_SPT_Manual_Sep_06.pdf Accessed August 8, 2008.
  16. Epton M, Town I, Ingham T, Wickens K, Fishwick D, Crane J, et al. The New Zealand Asthma and Allergy Cohort Study (NZA2CS): assembly, demographics and investigations. BMC Public Health. 2007;7:26
  17. Tannock G, Munro K, Harmsen H, Welling G, Smart J, Gopal P. Analysis of the fecal microflora of human subjects consuming a probiotic containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000;66:2578–2588
  18. Requena T, Burton J, Matsuki T, Munro K, Simon M, Tanaka R, et al. Identification, detection, and enumeration of human Bifidobacterium species by PCR targeting the transaldolase gene. Appl Environ Microbiol. 2002;68:2420–2427
  19. Walter J, Hertel C, Tannock G, Lis C, Munro K, Hammes W. Detection of Lactobacillus, Pediococcus, Leuconostic and WeisellaII species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis. Appl Environ Microbiol. 2001;67:2578–2585
  20. Ahrne S, Nobeck S, Jeppson B, Adlerberth I, Wold A, Molin G. The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol. 1998;85:88–94
  21. Janer C, Arigoni F, Lee B, Pelaez C, Requena T. Enzymatic ability of Bifidobacterium animalis subsp. lactis to hydrolyze milk proteins: identification and characterization to endopeptidase O. Appl Environ Microbiol. 2005;71:8460–8465
  22. Kim S-Y, Adachi Y. Biological and genetic classification of canine intestinal lactic acid bacteria and bifidobacteria. Microbiol Immunol. 2007;51:919–928
  23. Mah K, Chin V, Wong W, Lay C, Tannock G, Shek L, et al. Effect of milk formula containing probiotics on the fecal microbiota of Asian infants at risk of atopic diseases. Pediatr Res. 2007;62:674–679
  24. Osborn D, Sinn J. Probiotics in infants for prevention of allergic disease and food hypersensitivity. [review] Cochr Database Syst Rev. 2007;CD006474
  25. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol. 2008;121:116–121
  26. Perez P, Dore J, Leclerc M, Levenez F, Benyacoub J, Serrant P, et al. Bacterial imprinting of the neonatal immune system: lessons from maternal cells?. Pediatrics. 2007;119:E724–E732
  27. Prescott S, Bjorksten B. Probiotics for the prevention or treatment of allergic diseases. J Allergy Clin Immunol. 2007;120:255–262
  28. Niers L, Timmerman H, Rijkers G, van Bleek G, van Uden N, Knol E, et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy. 2005;35:1481–1489
  29. Prescott SL, Wicken K, Westcott L, Nieblee J, Currie H, Black P, et al. Supplementation with Loctobacillus, rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood IFN-γ and breast milk TGF-β and IgA detection. Clin Exp Allergy. 2008;In press
  30. Statistics New Zealand. 2006 NZ census of population and dwellings: QuickStats About Culture and Identity 2006 Census 2006. Available at: http://www.stats.govt.nz/census/2006-census-data/quickstats-about-culture-identity/quickstats-about-culture-and-identity.htm Accessed February 28, 2008.
  31. Ministry of Health . Tobacco trends 2006: monitoring tobacco use in New Zealand. Wellington: Ministry of Health; 2006;

 Supported by the Health Research Council of New Zealand and Fonterra Co-operative Group (Auckland, New Zealand). Fonterra Co-operative Group provided the study capsules and maintained quality control of the products throughout the study. All other aspects of the study were conducted independently of Fonterra Co-operative Group.

 Disclosure of potential conflict of interest: K. Wickens has received research funding from the Health Research Council and Fonterra Co-operative Group. P. N. Black has received research funding from the Health Research Council of New Zealand, the Child Health Research Foundation, Fonterra Co-operative Group, and Boehringer-Ingelheim. T. V. Stanley has received research funding from the Health Research Council of New Zealand, Fonterra Co-operative Group, the Asthma and Respiratory Foundation of New Zealand, and the Wellington Medical Research Foundation. E. Mitchell has received research funding from the Child Health Research Foundation and the National Heart Foundation of New Zealand and has served as trustee in the past year for the Wilson & Sweet Trust and the Child Health Research Foundation. P. Fitzharris has received research funding from the Marsden Fund and the Foundation for Research, Science & Technology. G. W. Tannock has received research support from the Marsden Fund and the Foundation for Research, Science, and Technology. G. Purdie has received research funding from the Health Research Council of New Zealand, Fonterra Co-operative Group, and the Ministry of Health. J. Crane has received research funding from the Health Research Council of New Zealand, Fonterra Co-operative Group, Rex Medical, the Asthma and Respiratory Foundation of New Zealand, and the National Institute of Environmental Health Sciences.

PII: S0091-6749(08)01319-5

doi: 10.1016/j.jaci.2008.07.011

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 788-794 , October 2008

Article Tools

* Image Usage & Resolution